While There's No Easy Rx for Drug Shortages, Pharma Groups Have Some Ideas
Industry groups suggest that the drug shortage crisis needs to be addressed by changing the economic model for reimbursement, while US FDA can help by making it easier for manufacturers to use “standby” facilities as needed to bridge supply gaps and by providing generic drug manufacturers with more notice on when applications will be approved.
You may also be interested in...
Non-profit intermediary being built by hospitals and health systems offers a private sector response to one of the deterrents to adequate supplies of important older generic drugs.
Problems persist at Pfizer’s US manufacturing facility in McPherson, Kansas, after an FDA audit led the agency to issue a ‘Form 483’ report with eight observations, seven of which were repeated from inspections dating back to as far as 2012.
Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.